-

FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices

  • Clearance expands connectivity and interoperability of the Dexcom CGM digital ecosystem
  • Allows invited third-party developers to connect applications and devices to real-time CGM data
  • Gives Dexcom users more choice in where and how they interact with their glucose data

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today U.S. Food and Drug Administration (FDA) clearance of the Dexcom Partner Web APIs, enabling invited third-party developers to integrate real-time CGM data into their digital health apps and devices.

“FDA clearance of our real-time APIs further solidifies Dexcom as the leader in interoperable CGM, giving Dexcom users even more choice in how they view and interact with their glucose data,” said Jake Leach, chief technology officer at Dexcom. “The new APIs will help seamlessly integrate the power of real-time Dexcom CGM data into some of the leading diabetes and digital health solutions.”

Several prominent diabetes and digital health companies have been invited to access the real-time APIs and are already in the testing and development phase, including Garmin® and Teladoc Health’s Livongo® for Diabetes.

“Garmin welcomes the opportunity to bring Dexcom CGM data to runners, cyclists and everyday users who rely on the technology 24/7 to proactively manage their diabetes,” said Joe Schrick, vice president of fitness at Garmin. “We are proud to be part of this integration that will allow users a secondary way to quickly and discreetly view estimated glucose levels and trends right from their smartwatch at any time.”

People with diabetes and their healthcare providers will benefit from the integration of real-time Dexcom CGM data into third-party apps and devices in a multitude of ways. For example, it will:

  • Allow users to quickly see all their therapy data in one place
  • Empower users to utilize the apps they find most beneficial for a more tailored Dexcom experience
  • Enable in-the-moment diabetes management coaching and feedback

For more information about the Dexcom real-time APIs and other offerings for third-party developers, visit Dexcom.com/WebAPI.

About DexCom, Inc.

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

Contacts

Media Contact:
James McIntosh, (619) 884-2118
Dexcom Public Relations
james.mcintosh@dexcom.com

Investor Contact:
Sean Christensen, (858) 203-6657
Dexcom Corporate Affairs
sean.christensen@dexcom.com

DexCom, Inc.

NASDAQ:DXCM

Release Summary
FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices
Release Versions
$Cashtags

Contacts

Media Contact:
James McIntosh, (619) 884-2118
Dexcom Public Relations
james.mcintosh@dexcom.com

Investor Contact:
Sean Christensen, (858) 203-6657
Dexcom Corporate Affairs
sean.christensen@dexcom.com

More News From DexCom, Inc.

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of...

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association’s Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e...

Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights...
Back to Newsroom